# Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

> **NCT05132907** · PHASE1 · COMPLETED · sponsor: **HDT Bio** · enrollment: 48 (actual)

## Conditions studied

- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** HDT-301

## Key facts

- **NCT ID:** NCT05132907
- **Lead sponsor:** HDT Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-24
- **Primary completion:** 2023-11-21
- **Final completion:** 2024-05-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132907, "Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05132907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*